Search

Displaying results 6871 - 6880 of 10000 in total
  1. Drug

    Vorinostat

    go.drugbank.com/drugs/DB02546
    ApprovedInvestigational

    A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier … Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease

    Products: ZOLINZA®VORINOSTAT 100 MG CAPSULAS
  2. Drug

    Dabocemagene autoficel

    go.drugbank.com/drugs/DB17878
    Investigational

    Dabocemagene autoficel is an ex vivo, autologous cell-based gene therapy. It comprises autologous dermal fibroblasts genetically modified to express functional type VII collagen. Developed by Castle Creek Biosciences Inc., dabocemagene a...

    Synonyms: -HUMAN CYTOMEGALOVIRUS PROMOTER/UTR-AND 3'-LTR/PO, D-Fi
  3. Drug

    Nilvadipine

    go.drugbank.com/drugs/DB06712
    Approved

    Nilvadipine is a calcium channel blocker (CCB) for the treatment of hypertension.

    Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingProducts: Tensan retard 8 mg - Kapseln, ESCOR 8MG RETARDKAPSELN
  4. Drug

    Octenidine

    go.drugbank.com/drugs/DB12624
    Investigational

    Octenidine is under investigation in clinical trial NCT02697162 (Antiseptic-coated Intermittent Urinary Catheter).

    Mixtures: Linola sept 1 mg/g + 10 mg/g Wund-Gel, Linola sept 1 mg/g + 20 mg/g Wund-Spray zur Anwendung auf der Haut, LösungCategories: Heterocyclic Compounds, 1-Ring
  5. Drug

    Apalutamide

    go.drugbank.com/drugs/DB11901
    ApprovedInvestigational

    In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment [A31846]. … In a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo [L1295].

    Categories: MATE 2 Inhibitors, MATE 1 InhibitorsProducts: ERLEADA ®TABLETAS RECUBIERTAS 60 MG
  6. Pathway

    Acylcarnitine 3-hydroxyhept-4-enoylcarnitine

    smpdb.ca/view/SMP0123355
    Metabolic

    Once in the matrix, 3-hydroxyhept-4-enoylcarnitine can react with the carnitine O-palmitoyltransferase 2 enzyme found in the mitochondrial inner membrane to once again form 3-hydroxyhept-4-enoyl-CoA and … 3-hydroxyhept-4-enoylcarnitine is an acylcarnitine.

    Drugs: Biotin · Adenosine phosphate · ATP · Levocarnitine · Magnesium cation · Pyrophosphoric acid +1 more
    Enzymes: Carnitine O-palmitoyltransferase 2, mitochondrial
  7. Pathway

    Acylcarnitine 4-amino-3-hydroxybutanoylcarnitine

    smpdb.ca/view/SMP0123475
    Metabolic

    Once in the matrix, 4-amino-3-hydroxybutanoylcarnitine can react with the carnitine O-palmitoyltransferase 2 enzyme found in the mitochondrial inner membrane to once again form 4-amino-3-hydroxybutanoyl-CoA … 4-amino-3-hydroxybutanoylcarnitine is an acylcarnitine.

    Drugs: Biotin · Adenosine phosphate · ATP · Levocarnitine · Magnesium cation · Pyrophosphoric acid +1 more
    Enzymes: Carnitine O-palmitoyltransferase 2, mitochondrial
  8. Drug

    Brodalumab

    go.drugbank.com/drugs/DB11776
    ApprovedInvestigational

    Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-sever...

    Categories: Interleukin-17 Receptor A Antagonist, Interleukin 17 Receptor A AntagonistsProducts: LUMICEF SUBCUTANEOUS INJECTION 210 MG SYRINGE
  9. Drug

    Gemtuzumab ozogamicin

    go.drugbank.com/drugs/DB00056
    ApprovedInvestigational

    Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody [FDA Label]. … It is also indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory) [L941].

    Products: MYLOTARG 5 MG IV İNFÜZYONLUK ÇÖZELTİ HAZIRLAMADA KULLANILACAK KONSANTRE İÇİN TOZ, 1 FLAKON, MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/VIAL
  10. Drug

    Icosapent ethyl

    go.drugbank.com/drugs/DB08887
    ApprovedInvestigationalNutraceutical

    Icosapent ethyl or ethyl eicosapentaenoic acid is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA). … It is used as an adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL) and to reduce the risk of cardiovascular events in certain patients with elevated triglycerides.

    Categories: Fatty Acids, Omega-3Synonyms: E-EPA, (all-Z)-5,8,11,14,17-Eicosapentaenoic acid ethyl ester